Key result
Cryoballoon ablation matches radiofrequency ablation for efficacy and safety in paroxysmal AF.
Why the study?
Does cryoballoon ablation provide noninferior efficacy compared to radiofrequency ablation in patients with drug-refractory paroxysmal atrial fibrillation?
Does cryoballoon ablation provide noninferior efficacy compared to radiofrequency ablation in patients with drug-refractory paroxysmal atrial fibrillation?
Cryoballoon ablation is a safe and effective alternative to radiofrequency ablation, demonstrating noninferiority for the treatment of drug-refractory paroxysmal atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Cryoballoon ablation expands options for drug-refractory paroxysmal AF; reinforces randomized evidence for its use alongside radiofrequency ablation.
In this randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect to efficacy for the treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no significant difference between the two methods with regard to overall safety. (Funded by Medtronic; FIRE AND ICE ClinicalTrials.gov number, NCT01490814.).
No takes yet. Share an insight, caveat, or question.
Kuck et al. (2016) studied this question. Cryoballoon ablation was noninferior to radiofrequency ablation for efficacy and had similar overall safety in patients with drug-refractory paroxysmal atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: